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Summary Introduction: Older patients are the most prevalent age cohort requiring
bronchoscopy. Prior sedation should be offered to improve patient comfort and
operator technical ease. Older patients have increased sensitivity to centrally acting
drugs increasing the procedural risk. This perceived risk may limit access to
bronchoscopy in older patients. There have been no systematic prospective placebo-
controlled studies in older patients. We compared a novel premedication regimen-
oral temazepam plus nebulised lignocaine (new treatment) to an established
regimen of intravenous alfentanyl (control).
Methods: Consecutive patients 75 years and older referred for bronchoscopy were
considered. Twenty-five patients were randomly assigned to each group. The primary
outcome measure was the lowest oxygen saturation recorded from the administra-
tion of IV drugs and for 30min post-bronchoscopy.
Results: The lowest mean oxygen saturation in the new treatment group was 92.2%
(90.3–94.2) and in the control group 91.1% (89.2–93.1). This was not statistically
different (P ¼ 0:370). There were no adverse events.
Conclusion: This is the largest prospective study to date on an older population
undergoing bronchoscopy supporting previous retrospective findings regarding the
safety of this procedure. Determined by oxygen saturations there is no difference in
safety between premedication regimens comprising oral temazepam/nebulised
lignocaine or intravenous alfentanyl.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Flexible fibreoptic bronchoscopy (bronchoscopy) is
a well-established and commonly used investiga-
tion in medicine. Its use is primarily in the diagnosis
and staging of endobronchial neoplasms. Lung
cancer remains predominantly a disease of older
people, who therefore constitute the major age
group requiring bronchoscopy.1
Although bronchoscopy remains a safe procedure
with a less than 0.3% complication rate,2 concern is
often expressed when an older patient is consid-
ered for bronchoscopy.
Sedation is generally considered to be worth-
while to improve patient comfort for what can be
an unpleasant procedure.3 It may also make the
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procedure easier for the bronchoscopist and the
patient more willing to accept further broncho-
scopy if required.
Ageing is associated with increased sensitivity to
some centrally acting sedative drugs,4,5 declining
lung function6 and increasing indications for
bronchoscopy. It is thus important to establish a
premedication regimen that minimizes both risk
and discomfort so that access to bronchoscopy is
not denied to older people on the basis of
inadequate evidence. There is no gold standard
regarding the choice of premedication in broncho-
scopy, although the benzodiazepines and opioids
are the most commonly used.7
There have been no prospective systematic
comparisons of different premedication regimens
in older patients.
Hypothesis
An oral benzodiazepine (temazepam) plus nebu-
lised lignocaine exhibits greater safety (with
comparable tolerability) when compared with a
parenteral opioid (alfentanyl) in older patients
undergoing bronchoscopy.
Methods
Patients and procedures
We performed a prospective double-blind rando-
mised placebo-controlled trial on 50 patients 75
years and over who required bronchoscopy. Con-
secutive patients referred to the primary investi-
gators bronchoscopy list were considered. All
patients had a full history and physical examination
as well as a review of the case notes. Patients were
excluded if taking any benzodiazepine or opioid, as
were patients with a resting oxygen saturation of
less than 90% on room air, an abbreviated Mental
Test Score of less than 7/108 or those with an
inability to perform a visual analogue scale.9
Written consent was obtained.
The study was carried out in three centres. Ethics
committee approval was obtained independently in
each centre.
All bronchoscopies were performed by the same
investigator (MW). The primary endpoint of the
study was the lowest oxygen saturation recorded
throughout and 30min post procedure. A sample of
25 patients in each treatment group were sufficient
to achieve 80% power at the 5% significance level,
assuming, the difference in the average reduction
in oxygen saturation of 5% in one group and 7% in
the other, with a standard deviation in each group
of 2.5%.
Twenty-five patients were randomised to the
‘‘new treatment’’ group, receiving 10mg oral
temazepam 1h before the procedure, 4ml of 2%
lignocaine nebulised 30min before, ‘‘spray as you
go’’ lignocaine through the working canal and 1–
2ml placebo (0.9% NaCl) IV at T0 (Fig. 1).
Twenty-five patients were randomised to the
‘‘normal treatment’’ group, receiving a placebo
tablet (SAC LAB) 1 h before the procedure, 4ml
placebo (0.9% NaCl) nebulised 30min before,
‘‘spray as you go’’ lignocaine and 250–500mcg of
IV alfentanyl (BMlo23, 250mcg, BMlX23, 500mcg)
at T0 (Fig. 1).
The study was double blind and placebo con-
trolled. All medications of both regimens were
matched for tablet and vial size, with original
labels obscured. Oral medications and nebulisers
were administered by nursing staff. Intravenous
mediations were administered by the primary
investigator (MW).
All nebulisers were administered using a sys-
tem22 model supplied by oxygen care.
In both groups, a combination of 2% and 4%
lignocaine was used as per the ‘‘spray as you go’’
method through the working canal, the dose
determined by the bronchoscopist as per the usual
method.
Oxygen saturations were recorded every 15 s
from the administration of intravenous drugs, and
for 30min post procedure (using standard pulse
oxymetry).
All patients received 2 l of oxygen by nasal
prongs, and any additional oxygen was recorded.
Spirometry was performed pre- and post-broncho-
scopy (using a calibrated Vitallograph spirometer).
The procedure was recorded on audiotape and
cough indices subsequently calculated. A paroxysm
or episode of coughing was given a score of 1. The
volume of topical lignocaine used was recorded,
cardiac rhythm was monitored and any deviations
from base line documented. Visual analogue scales
were used to assess patient comfort, willingness to
undergo a repeat bronchoscopy and operator
assessment of sedation. Patient visual analogue
scores were repeated 24 h post bronchoscopy and
returned by post.
Statistical analysis
All data were assessed for normality. The signifi-
cance of normally distributed data was assessed
using Student’s t-tests, and of non-normally dis-
tributed data using the Mann–Whitney U test.
ARTICLE IN PRESS
Comparison of premedication regimens 221
Results
There was no statistically significant difference in
age, gender, and base line lung function and resting
oxygen saturations on air pre bronchoscopy in both
groups (Table 1).The mean age in the new treat-
ment group was 81.6 (95% CI 79.6–83.8) and in the
normal treatment group 80.5 (95% CI 78.2–82.7).
Findings at bronchoscopy are summarised in
Table 2. The distribution of endobronchial carcino-
ma and infection were equal in each group. All
patients with visible endobronchial lesions had
positive biopsies.
The lowest oxygen saturation recorded in the
new treatment group was 92.2% (95% CI 90.3–94.2)
and 91.1% (95% CI 89.2–93.1) in the normal
treatment group (Fig. 2). This variable was close
to being normally distributed and thus both para-
metric and non-parametric tests were performed.
Neither test revealed a statistically significant
difference between the two groups. P ¼ 0:370 and
0.416, respectively (Table 1).
There was no statistically significant diffe-
rence in lung function in both treatment group’s
pre and post bronchoscopy (Table 3). There was a
statistically significant reduction in coughing par-
oxysms in the new treatment group (the median
cough index of the new treatment group was 4,
and 10 in the normal treatment group Po0.0005
(Table 4).
There was a statistically significant lower opera-
tor recorded sedation score in the new treatment
group, 2.22 (95% CI 1.56–2.87) versus 3.77 (95% CI
2.44–5.10), P¼ 0.037 (Table 4).
There was a statistically significantly lower total
dose of topical lignocaine (inclusive of nebuliser)
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Figure 1 Trial profile.
Table 1
Variable New treatment (temazepam
plus nebulised lignocaine)
Normal treatment
(alfentanyl)
P-value
Age (mean795% confidence) 81.6 (79.3/83.8) 80.5 (78.2/82.7) 0.49
Gender (male: female) 12:13 12:13 N/A
Oxygen saturation (%) 92.2 (90.3/94.2) 91.1 (89.2/93.1) 0.416
(mean795% confidence) 0.370
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used in the new treatment group, median¼ 294mg
versus median¼ 472mg in the control group, P ¼
0:0005 (Table 4).
There was no difference in the additional use of
oxygen in either group. Patient derived visual
analogue scores of discomfort both immediately
after the procedure and the next day were
significantly lower in the new treatment group
(P ¼ 0:019), and the next day (Po0:0005) (Table 5).
Willingness to undergo a repeat bronchoscopy was
significantly greater in the new treatment group,
both immediately after (P ¼ 0:031) and the next
day (P ¼ 0:006). 100% of the next day postal
questionnaires were returned.
There were no procedure-related adverse events
in either group.
Discussion
This is the first prospective double blind rando-
mised controlled study of a specifically elderly
group of patients requiring bronchoscopy. There
have been no controlled studies that clearly
delineate the factors (including age) that makes
an individual patient unsuitable for bronchoscopy.
Thus the decision to carry out the procedure is
made assessing the likelihood of obtaining a
diagnosis and a clinical judgement of risk to the
patient. The latter is often somewhat subjective,
but may include variables such as lung function,
oxygen saturation on air and the perceived ‘‘gen-
eral frailty’’ of a patient. Despite this, broncho-
scopy remains an extremely safe procedure with
mortality rates around 0.01%, and major com-
plications of 0.3% in a series of about 48,000
procedures.2
Chronological age is still sometimes invoked as a
deterrent to the carrying out of any procedure with
perceived or actual risk attached. To date the
majority of studies looking at age with respect to
bronchoscopy have been retrospective, simply
including older patients in their analysis, rather
than studying them specifically. Thus the evidence
regarding safety in older patients in terms of
prospective placebo-controlled trials is poor if not
absent. In view of the well-reported age-associated
changes in pharmacological response for some
centrally acting agents,4,5 this is unsatisfactory.
It is generally accepted amongst respiratory
physicians that sedation should be offered to
patients who are about to undergo bronchoscopy.3
This not only improves patient comfort but may
also make the procedure easier for the bronchos-
copist. The choice of sedation however remains
variable. Both the opioids and benzodiazepines are
widely used and studied. The major difference
between the two identified is the well-established
retrograde amnesic effect of the benzodiazepines,
and the subsequent increased willingness for
patients to accept another bronchoscopy.10
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Table 2 Findings at bronchoscopy.
Diagnostic categories New treatment (temazepam
plus nebulised lignocaine)
Normal treatment (alfentanyl)
Bronchogenic carcinoma (total) 11 10
Squamous cell 8 5
Adenocarcinoma 2 4
Small cell 1 1
Infection (total) 2 3
Tuberculosis 1 1
Other (total) 1 2
Other 4 3
Telangectasia 1 0
Extrinsic compression 3 3
Normal 8 9
Figure 2 Lowest oxygen saturation (%).
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Older patients have a well-documented in-
creased incidence of adverse drug reactions, and
specifically an increased sensitivity to centrally
acting drugs. This is true of both benzodiazepines5
and the opioids.4 Despite these concerns there are
no evidence-based guidelines for the sedation of
older patients undergoing bronchoscopy.
We chose to compare on oral benzodiazepine plus
nebulised lignocaine to an intravenous opioid. Oral
temazepam is thought to cause less respiratory
compromise and to have a retrograde amnesic
effect. Intravenous alfentanyl, a short acting
opioid, is thought to be more sedating and thus
comfortable for patients, as well as having a
significant anti-tussive effect.
The primary endpoint of this study was the
lowest oxygen saturation recorded during and
30min post procedure. Although the alfentanyl
group mean oxygen saturation (91.1%) was approxi-
mately 1% lower than the temazepam group (92.2%)
this did not reach statistical significance. This
however may in part relate to the variable
measured and thus the design of the study. At and
around the 91–92% level, the haemoglobin oxygen
disassociation curve begins to decline steeply. Thus
small changes in the oxygen saturation can reflect
significantly greater changes in the partial pressure
of oxygen (PO2) dissolved directly in the serum
and available to supply tissues. Hence the 1.1%
difference in oxygen saturation may represent a
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Table 4
Variable New treatment (temazepam
plus nebulised lignocaine)
Normal treatment
(alfentanyl)
P-value
Cough indices (median) 4 10 o0.0005
Sedation (mean795% confidence) 2.22 (1.56/2.87) 3.77 (2.44/5.10) 0.037
Total dose of lignocaine (mg) (median) 294 472 o0.0005
Additional oxygen vol (l) (median) 0 0 0.934
Table 5 Patient visual analogue scales.
Variable New treatment (temazepam
plus nebulised lignocaine)
Normal treatment
(alfentanyl)
P-value
Discomfort T0 (median) 1.5 4.0 0.019
Discomfort T0þ 24 h (median) 1.0 5.0 o0.0005
Another bronchoscopy T0 (median) 2.0 5.0 0.031
Another bronchoscopy T0þ 24 h
(median)
1.0 3.0 0.0006
Table 3 Lung function.
Variable New treatment (temazepam
plus nebulised lignocaine)
Normal treatment
(alfentanyl)
P-value
FEV1 (L) pre-bronch
(mean795% confidence)
1.27 (1.02/1.5) 1.26 (1.1/1.4) 0.938
FVC (L) pre-bronch
(mean795% confidence)
1.73 (1.43/2.04) 1.85 (1.5/2.18) 0.611
FEV1/FVC (%) Pre-bronch
(mean795% confidence)
71.6 (66.5/77.7) 70.0 (64.1/75.8) 0.664
FEV1 (L) post-bronch 1.09 (0.86/1.32) 0.99 (0.83/1.14) 0.445
(mean795% confidence) 0.192
FVC (L) post-bronch 1.49 (1.18/1.80) 1.44 (1.21/1.68) 0.808
(mean795% confidence) 0.111
FEV1/FVC (%) post-bronch 70.8 (66.6/75.0) 68.5 (63.2/73.8) 0.491
(mean795% confidence) 0.850
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clinically significant reduction in the PO2. However,
the logistics of continuous PO2 measurement are
such that this was not undertaken in this study.
Bronchoscopy is associated with a decline in lung
function.2 There was however no statistically
significant difference in its decline between our
two groups. This is despite there being a statisti-
cally significant reduction of operator assessment
of sedation in the alfentanyl group. P ¼ 0:037
(Table 3).
Lignocaine is the most commonly used local
anaesthetic in bronchoscopy. The most common
method is ‘‘spray as you go’’, under direct vision
with a 2–4% solution. A previous study looking at
lung function pre and post bronchoscopy, found the
volume of topical lignocaine used was a significant
contributor to its decline post bronchoscopy.11 The
use of nebulised lignocaine compared to N Saline
prior to bronchoscopy was found by Foster and
Hurewitz12 to significantly reduce the volume of
topical lignocaine required in both the upper and
lower airways. Despite this, the use of a lignocaine
nebuliser pre bronchoscopy is not widely studied.
The British Thoracic Society guidelines (2001)
recommend the total dose should be limited to
8.2mg/kg with ‘‘extra care’’ in the elderly, and
that 4% nebulised lignocaine can anaesthetize the
oropharynx and vocal cords.3 Thus a 4ml 2%
lignocaine nebuliser was added to the temazepam
group (new treatment), and controlled for with a
4ml 0.9% NaCL nebuliser in the IV alfentanyl group
(normal treatment).
This study is the first to show a statistically
significant reduction in coughing with nebulised
lignocaine when compared to placebo in adults
undergoing bronchoscopy (Table 3). Coughing is
both unpleasant for patients and may be techni-
cally compromising for the bronchoscopist. It is
generally accepted that benzodiazepines as a group
have little effect on cough apart from their general
sedative effects, whereas the opioids are known to
have a centrally acting anti-tussive effect. Thus the
use of a 4ml 2% lignocaine nebulised 30min prior to
bronchoscopy may account for the observed reduc-
tion in cough in the new treatment group. We have
also shown that when nebulised lignocaine was
used there was a statistically significant reduction
in the mean dose of topically administered ligno-
caine (294mg versus 472mg) P ¼ 0:0005: This is
supported by the previous findings of Foster and
Hurewitz12 Given that lignocaine is readily ab-
sorbed into the circulation during bronchoscopy,
the use of a lignocaine nebuliser in older patients
undergoing bronchoscopy may reduce the total
dose of lignocaine absorbed into the circulation and
hence limit adverse events.
Patient assessment of discomfort using a 10cm
visual analogue scale was generally low in both
groups (2.42 versus 3.62). There was however a
significantly less-reported discomfort in the tema-
zepam/nebulised lignocaine group both immediately
and 24h after bronchoscopy (P ¼ 0:019; 0.0005).
Similarly willingness to undergo a repeat proce-
dure was significantly greater in the temazepam/
nebulised lignocaine group immediately after the
procedure. (P ¼ 0:031) This difference was main-
tained at 24 h (P ¼ 0:006).
Conclusion
Although the primary end point of this study did not
achieve statistical significance for the difference
between regimens, our findings point to the overall
superiority for use in older patients of a premedi-
cation of oral temazepam/nebulised lignocaine
when compared to intravenous alfentanyl in older
patients undergoing bronchoscopy. There were
clear advantages in terms of patient assessment
of comfort, willingness to undergo a repeat
bronchoscopy, the objective measurement of
coughing and the topical dose of lignocaine used.
This study also supports previous reports con-
firming the safety of fibreoptic bronchoscopy in
older patients. Although the numbers in this study
were not large enough to make an overall state-
ment about safety, it does explore further ways in
which risk might be minimized.
Within the combined regimen used our findings
also suggest advantages in the use of 4ml 2%
lignocaine nebulised 30min prior to bronchoscopy.
By reducing the total dose of lignocaine required
systemic absorption and thus potential adverse
effects may be minimised. Equally cough and
patient comfort appear to be improved. This may
be applicable to all adult patients.
This study was not however specifically designed
to look at the effect of a nebulised lignocaine
alone.
Finally this study did not have a ‘‘no sedation’’
group. Although the BTS recommend sedation,3
there is often the expressed view amongst bronch-
oscopists that older patients in particular seem to
tolerate bronchoscopy better than younger pa-
tients. Despite there being no evidence for this
view in the literature, it may be an area worthy of
further study.
Equally many centres prefer benzodiazepines as
their intravenous agent of choice, particularly since
the advent of a specific antagonist (flumazenil).
This is also worthy of further study.
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Finally given the age profile of patients under-
going bronchoscopy, there remains a dearth of
evidence in the literature regarding the influence
of age on selection criteria and premedication
choice. This is an area worthy of further prospec-
tive investigation. Our experience in this study
suggests there is no practical reason why this and
other necessary related research should not be
carried out in the relevant patient population.
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